| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $52,930,187 ) (Continued on the next page) |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA286160 | Targeting Immune Escape in CML/MPN Transformation | 000 | 3 | NIH | 12/12/2025 | $514,454 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA279595 | Targeting Protein Arginine Methyltransferases to Eradicate Acute Myeloid Leukemia | 001 | 3 | NIH | 4/16/2026 | $70,805 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA279595 | Targeting Protein Arginine Methyltransferases to Eradicate Acute Myeloid Leukemia | 000 | 3 | NIH | 12/15/2025 | $637,252 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA258981 | The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML | 001 | 5 | NIH | 4/16/2026 | $54,289 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA258981 | The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML | 000 | 5 | NIH | 12/22/2025 | $488,601 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | K23AI163343 | Cytomegalovirus-specific Immune Reconstitution after Hematopoietic Cell Transplantation in the Era of Modern Antiviral Prophylaxis | 001 | 7 | NIH | 1/26/2026 | $187,540 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01DK138665 | Targeting bile acid composition to treat metabolic diseases | 000 | 3 | NIH | 12/18/2025 | $665,898 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA241845 | Validation of epigenomic biomarkers for thyroid cancer diagnostics | 001 | 5 | NIH | 4/16/2026 | $81,787 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA241845 | Validation of epigenomic biomarkers for thyroid cancer diagnostics | 000 | 5 | NIH | 12/10/2025 | $736,086 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA258778 | Targeting tumor-associated macrophages for triple-negative breast cancer treatment | 001 | 5 | NIH | 4/16/2026 | $51,959 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA258778 | Targeting tumor-associated macrophages for triple-negative breast cancer treatment | 000 | 5 | NIH | 12/11/2025 | $467,633 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R25CA275711 | Cancer Aging and Metabolism research experience Program (CAMP) | 001 | 3 | NIH | 6/12/2026 | $231,762 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | P30CA033572 | Cancer Center Support Grant | 003 | 43 | NIH | 6/29/2026 | $221,720 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | P30CA033572 | Cancer Center Support Grant | 002 | 43 | NIH | 4/16/2026 | $401,349 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | P30CA033572 | Cancer Center Support Grant | 001 | 43 | NIH | 2/13/2026 | $3,612,130 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01HL162847 | Pathogenesis, prevention and treatment of corticosteroid-resistant gut GVHD | 001 | 4 | NIH | 6/18/2026 | $0 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01HL162847 | Pathogenesis, prevention and treatment of corticosteroid-resistant gut GVHD | 000 | 4 | NIH | 6/10/2026 | $839,592 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA266665 | Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer | 001 | 5 | NIH | 1/28/2026 | $556,363 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA269740 | Targeting the Microenvironment/Oncogene Cooperation to treat poor prognosis T-ALL | 001 | 4 | NIH | 4/17/2026 | $51,967 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA269740 | Targeting the Microenvironment/Oncogene Cooperation to treat poor prognosis T-ALL | 000 | 4 | NIH | 2/18/2026 | $467,705 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA266874 | A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer | 000 | 5 | NIH | 7/3/2026 | $704,036 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | T32DK131943 | DIABETES PREVENTION / RISK / OMICS / METABOLISM / THERAPY (PROMT) INTERDISCIPLINARY TRAINING | 001 | 4 | NIH | 4/1/2026 | $2,488 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | T32DK131943 | DIABETES PREVENTION / RISK / OMICS / METABOLISM / THERAPY (PROMT) INTERDISCIPLINARY TRAINING | 000 | 4 | NIH | 3/27/2026 | $89,205 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01ES034793 | Early Life Exposure to Endocrine Disrupting Chemicals: Epigenomic and Transcriptomic Networks and RAGE in Liver Disease | 000 | 3 | NIH | 4/10/2026 | $767,661 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA266659 | The Novel Role and Mechanism of RBM33 in Leukemogenesis | 003 | 5 | NIH | 4/6/2026 | $473,946 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA266659 | The Novel Role and Mechanism of RBM33 in Leukemogenesis | 002 | 5 | NIH | 4/2/2026 | -$473,946 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA266659 | The Novel Role and Mechanism of RBM33 in Leukemogenesis | 001 | 5 | NIH | 3/20/2026 | $473,946 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01ES033514 | Environmental Chemical Body Burden and Prospective Breast Cancer Risk in the Cancer Prevention Study-3 Cohort | 000 | 5 | NIH | 4/28/2026 | $608,813 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA271497 | The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia | 000 | 5 | NIH | 4/17/2026 | $574,091 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | UM1CA186717 | Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN | 001 | 9 | NIH | 6/11/2026 | $1,915,725 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA262263 | Understanding the Increased Risk of Childhood Acute Lymphoblastic Leukemia in Latinos | 001 | 5 | NIH | 6/30/2026 | $690,799 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA261793 | Leveraging Digital Health Solutions to Reduce Learning and Functional Disparities in Children with Cancer | 001 | 5 | NIH | 6/26/2026 | $512,135 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R37CA292678 | The role, mechanism, and therapeutic potential of METTL1 in acute myeloid leukemia | 000 | 3 | NIH | 7/1/2026 | $429,139 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | U01CA299594 | An exosome-based liquid biopsy assay for the non-invasive early detection of colorectal adenomas and cancers | 000 | 1 | NIH | 3/16/2026 | $738,675 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01HL173308 | Novel mechanisms and therapeutics for Tyrosine Kinase Inhibitor-induced Cardiotoxicity | 001 | 2 | NIH | 3/20/2026 | $21,701 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01HL173308 | Novel mechanisms and therapeutics for Tyrosine Kinase Inhibitor-induced Cardiotoxicity | 000 | 2 | NIH | 2/23/2026 | $687,181 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01NS132083 | Biological function and regulation of PRMT9 in synapse development | 001 | 3 | NIH | 3/3/2026 | $59,488 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01NS132083 | Biological function and regulation of PRMT9 in synapse development | 000 | 3 | NIH | 1/23/2026 | $535,402 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA301510 | Discovery and validation of CYP8B1 Inhibitors as probes for targeting Hepatocellular Carcinomas (HCC) | 000 | 2 | NIH | 4/9/2026 | $772,905 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA299039 | The role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression | 000 | 2 | NIH | 3/31/2026 | $573,528 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01NS138604 | High Fidelity Genome Editing for the Correction of MECP2 Mutations and Physiologic Regulation of Expression in Rett Syndrome | 000 | 2 | NIH | 2/25/2026 | $718,682 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA228308 | The role of bile acid metabolomics in graft-versus-host disease | 000 | 9 | NIH | 4/21/2026 | $585,843 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R25CA217270 | Preparing Oncology Advanced Practice Nurses as Generalists in Palliative Care | 001 | 9 | NIH | 5/4/2026 | $4,800 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R25CA217270 | Preparing Oncology Advanced Practice Nurses as Generalists in Palliative Care | 000 | 9 | NIH | 3/25/2026 | $226,709 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | T32CA186895 | DNA Damage Response and Oncogenic Signaling | 001 | 10 | NIH | 4/16/2026 | $4,122 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | T32CA186895 | DNA Damage Response and Oncogenic Signaling | 000 | 10 | NIH | 2/24/2026 | $239,954 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA292596 | Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous Leukemia | 001 | 2 | NIH | 3/3/2026 | $738,698 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01HL171309 | Integrative role of Rps6kb1 in pathological cardiac remodeling | 000 | 3 | NIH | 4/28/2026 | $829,606 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R35GM156316 | Protein arginine methylation in transcription and RNA metabolism | 001 | 2 | NIH | 3/19/2026 | $44,500 |
|
